News

Waste, cost and carbon are converging to reshape how cataract centres choose instruments.

Home OCT now gives us the next dimension: time.

In this Q&A, Vance Thompson, MD, clears up myths about dry eye and LASIK wearing off, and explains how better screening and technology are making the procedure more precise for younger patients.

Findings highlight the need for routine bilateral endothelial assessment in herpetic eye disease

Choosing the right IOL for patients seeking spectacle independence is increasingly complex as novel optical designs enter the field. This comparative case report explores how a proven diffractive trifocal IOL (AT LISA tri 839MP) performs against a novel spiral optic IOL and what the real-world trade-offs mean for patient selection.

Shortcomings of early 27-G vitrectomy systems drove the development of new technologies designed to match or surpass the performance of larger-gauge systems. The DORC TDC VELOCE represents the latest advancement - a next-generation high-speed cutter that reaches its full potential when combined with the DORC EVA NEXUS surgical system.

The phase 2 Early Vitrectomy and Intravitreal Antibiotics for Post-Operative Exogenous Endophthalmitis study showed that performing early vitrectomy for acute endophthalmitis can offer better and faster visual outcomes than the current treatment of prescribing antibiotics first.

Susvimo works in conjunction with the company’s port delivery platform, Contivue, which was specifically engineered for use with Susvimo.

Why AI-driven functional imaging could change how clinicians assess and treat retinal disease

David E. I. Pyott, CBE, MD(Hon), MBA, MA, discusses expanding subspecialty training and internationally recognized credentials in underserved regions.

A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.

The long-term outcomes after primary scleral buckling procedures for rhegmatogenous retinal detachments showed high anatomic success, improved vision, and a good safety profile.

Antineoplastics were the most frequently implicated drug class in review

Real-world data support EndoArt as donor-independent option in high-risk patients

Andy Chang and Mikhail Boukhny of BVI Medical discuss the company's new Experience Hub in Sant Cugat, Spain, a hands-on training facility built to gather surgeon feedback ahead of the Virtuoso platform's European launch.

Biologic therapies linked to high remission rates over 2-year follow-up

Researchers identify microbial shifts tied to corneal disease history

Deeper anterior chamber depth and shorter disease course predicted better surgical outcomes

Ectoine eye drops boost tear stability and ease redness and tired eyes, along with burning, foreign body and dryness sensations, offering fast, irritation-free relief for patients with dry eye disease.

The US FDA approves Lumvoa for TED in active or chronic stages, showing rapid proptosis and diplopia improvements; safety monitoring includes hearing, hyperglycemia and infusion reactions.

Real-world data show dexamethasone intravitreal implant improves vision and thickness in RVO macular edema, with earlier anti-VEGF switching yielding better gains.

Charlie Zhang, MD, reflects on the rising incidence, diagnostic challenges and multidisciplinary management of immune checkpoint inhibitor–associated uveitis

Piotr Woźniak, MD, PhD, shares real-world evidence on Artelac Complete in dry eye disease from EuDEC 2026 in Milan, Italy, including improvements in tear break-up time and Schirmer scores, perioperative and contact lens use patterns, and high eye care practitioner satisfaction.

Researchers assessed accommodative changes after foldable iris-fixated phakic IOL implantation for myopic astigmatism

AI models predicting retinal function from OCT could transform geographic atrophy assessment in clinical care and trials

This is a promotional supplement commissioned by Roche Products Limited.

Two cases highlight the diagnostic challenges of Demodex blepharitis and underscore the unmet need for approved targeted therapies in the United Kingdom.

Utilize oral agents, diet and glucose monitoring systems when acting to preserve vision